AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20919540 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion therapy based on routine hemodynamic parameters (blood pressure, heart rate, central venous pressure, daily fluid balance)
Number of subjects: 45
Study 20919540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontraumatic intracranial hemorrhages
Number of subjects: 45
Study 20919540 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe brain injury
Number of subjects: 45
Study 18431264 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP (0.01‐0.05 microg/kg/min)
Number of subjects: 40
Study 17075113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation by irradiation
Number of subjects: 762
Study 17075113 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 762
Study 14594437 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alfa
Number of subjects: 55
Study 14594437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11200917 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock patients
Number of subjects: 25
Study 9005122 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg before breakfast)
Number of subjects: 95
Study 9005122 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg before bedtime)
Number of subjects: 95
Study 1377118 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF)
Number of subjects: 0
Study 3977145 — intervention group
Group type: EXPERIMENTAL
Intervention: Military antishock trousers (MAST)
Number of subjects: 68
Study 3977145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MAST)
Number of subjects: 68
Study 31005969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU monthly)
Number of subjects: 5110
Study 31005969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study 28936962 — intervention group
Group type: EXPERIMENTAL
Intervention: New type of tracheal catheter fixation tape
Number of subjects: 90
Study 28936962 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical adhesive tape and fixation belt
Number of subjects: 90
Study 26297722 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsory vaccination intervention (n = 144)
Number of subjects: 297
Study 26297722 — intervention group
Group type: COMPARATOR
Intervention: Voluntary vaccination control group (n = 153)
Number of subjects: 297
Study 25129485 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-Strips Dry® with Veritas® (PSD-V)
Number of subjects: 100
Study 25129485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no buttress material)
Number of subjects: 100
Study 22491410 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching therapy (1 hour per day per month of age until 8 months, then 50% of waking hours thereafter)
Number of subjects: 108
Study 19449344 — intervention group
Group type: EXPERIMENTAL
Intervention: Danshen dripping pill (DDP)
Number of subjects: 106
Study 19449344 — intervention group
Group type: COMPARATOR
Intervention: Non-DDP treatment (Control)
Number of subjects: 106
Study 17942272 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned advance directive (fifth grade reading level with graphics)
Number of subjects: 205
Study 17942272 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned advance directive
Number of subjects: 205
Study 17942272 — intervention group
Group type: COMPARATOR
Intervention: Standard advance directive (>12th grade level)
Number of subjects: 205
Study 17942272 — intervention group
Group type: COMPARATOR
Intervention: Standard advance directive
Number of subjects: 205
Study 15388301 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year-olds in Experiment 1 when the sought entity was a person
Number of subjects: 153
Study 15388301 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year-olds in Experiment 1 when the sought entity was a physical object
Number of subjects: 153
Study 15388301 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year-olds in Experiment 2 when asked where the searching protagonist would look first
Number of subjects: 153
Study 15388301 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year-olds in Experiment 2 when asked what the protagonist would do next
Number of subjects: 153
Study 15388301 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year-olds in Experiment 2 with the word 'first' in the question
Number of subjects: 153
Study 11208681 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (25 mg/d)
Number of subjects: 141
Study 11208681 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 141
Study 9413448 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric muscle contractions
Number of subjects: 40
Study 9413448 — intervention group
Group type: COMPARATOR
Intervention: Eccentric muscle contractions
Number of subjects: 40
Study 9413448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8500862 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 17
Study 8500862 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17
Study 8500862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 17
Study 8500862 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 17
Study 8500862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3628831 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine HCl (0.25, 0.5, 0.75, 1.0 mg sc)
Number of subjects: 8
Study 3628831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5-3.75 mg/d po)
Number of subjects: 8
Study 3628831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29587666 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 29587666 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed-cisplatin
Number of subjects: 0
Study 27574998 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (≥60 seconds)
Number of subjects: 266
Study 27574998 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (<10 seconds)
Number of subjects: 266
Study 23805799 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 180
Study 22074912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictographs (shaded blocks)
Number of subjects: 120
Study 22074912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictographs (unshaded dots)
Number of subjects: 120
Study 22074912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar charts (medium numerators)
Number of subjects: 120
Study 22074912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictographs (small numerators)
Number of subjects: 120
Study 22074912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar charts (medium/large numerators)
Number of subjects: 120
Study 20679835 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silicone gel
Number of subjects: 23
Study 18639628 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 36
Study 18639628 — intervention group
Group type: COMPARATOR
Intervention: Non-relaxation
Number of subjects: 36
Study 15883488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% mequitazine
Number of subjects: 24
Study 15883488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% levocabastine
Number of subjects: 24
Study 15883488 — intervention group
Group type: COMPARATOR
Intervention: 0.1% dexamethasone
Number of subjects: 24
Study 12520633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin with calcium-fortified orange juice
Number of subjects: 16
Study 12520633 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin with water
Number of subjects: 16
Study 12520633 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin with nonfortified orange juice
Number of subjects: 16
Study 10760725 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate (OC)
Number of subjects: 42
Study 10760725 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 42
Study 8770475 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, unedited analyses of phantom images
Number of subjects: 11
Study 8770475 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical image analysis using differing QCA systems
Number of subjects: 11
Study 1300301 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% Flurbiprofen‐Na+ eye drops 1/2 hourly starting two hours before surgery
Number of subjects: 50
Study 1300301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no flurbiprofen)
Number of subjects: 50
Study 1300301 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% Flurbiprofen‐Na+ eye drops
Number of subjects: 50
Study 6543134 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (100-200 mg/day for 7-14 days)
Number of subjects: 11
Study 6543134 — intervention group
Group type: COMPARATOR
Intervention: Stage-matched control group
Number of subjects: 11
Study 31622058 — intervention group
Group type: EXPERIMENTAL
Intervention: Allokin-alpha therapy (9 injections of s/c, 1.0 mg every other day)
Number of subjects: 59
Study 31622058 — intervention group
Group type: COMPARATOR
Intervention: Valtrex (500 mg x 2 times/day, by mouth for two months)
Number of subjects: 59
Study 31168175 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic platelet gel
Number of subjects: 60
Study 31168175 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel
Number of subjects: 60
Study 26317300 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased workloads (0.5, 1, 1.5, 2, and 2.5 kg at 60 rpm)
Number of subjects: 18
Study 26317300 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cadences (70, 80, and 90 rpm with 1-kg workload)
Number of subjects: 18
Study 26317300 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased workloads at constant cadence
Number of subjects: 18
Study 24274958 — intervention group
Group type: EXPERIMENTAL
Intervention: Delaire-type facemask (FM)
Number of subjects: 65
Study 24274958 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tandem traction bow appliance (MTTBA)
Number of subjects: 65
Study 24274958 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed without treatment)
Number of subjects: 65
Study 22709731 — intervention group
Group type: EXPERIMENTAL
Intervention: Training professionals in assisted living facilities (two half-day sessions)
Number of subjects: 212
Study 22709731 — intervention group
Group type: COMPARATOR
Intervention: Usual care procedures and delayed training (control group)
Number of subjects: 212
Study 20160081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin inhalation
Number of subjects: 13
Study 18072057 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 100
Study 18072057 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 100
Study 16238894 — intervention group
Group type: EXPERIMENTAL
Intervention: GAL-ER 24 mg qd (fasted)
Number of subjects: 24
Study 16238894 — intervention group
Group type: EXPERIMENTAL
Intervention: GAL-ER 24 mg qd (fed)
Number of subjects: 24
Study 16238894 — intervention group
Group type: COMPARATOR
Intervention: GAL-IR 12 mg bid (fasted)
Number of subjects: 24
Study 12387474 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture closure (3‐0 Dexon II)
Number of subjects: 250
Study 12387474 — intervention group
Group type: COMPARATOR
Intervention: Adhesive strip closure (Steri‐Strip)
Number of subjects: 250
Study 10628237 — intervention group
Group type: EXPERIMENTAL
Intervention: Family life education program (abstinence-based adolescent pregnancy prevention program)
Number of subjects: 251
Study 10628237 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment condition (control)
Number of subjects: 251
Study 7769096 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate (VS) 100 mg/d for 3 weeks
Number of subjects: 6
Study 2311809 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intramuscular bromocriptine retard
Number of subjects: 108
Study 2311809 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg intramuscular bromocriptine retard
Number of subjects: 108
Study 2311809 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intramuscular bromocriptine retard
Number of subjects: 108
Study 2311809 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intramuscular bromocriptine retard
Number of subjects: 108
Study 6810298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier for nonnutritive sucking during tube feedings
Number of subjects: 0
Study 6810298 — intervention group
Group type: COMPARATOR
Intervention: Control group infants (no pacifier)
Number of subjects: 0
Study 31795482 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT-120 (60 or 120 mg/kg)
Number of subjects: 70
Study 31795482 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT-60 (60 or 120 mg/kg)
Number of subjects: 70
Study 31795482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31795482 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT-60
Number of subjects: 70
Study 31795482 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT-120
Number of subjects: 70
Study 29779416 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (110/50 μg once daily)
Number of subjects: 1053
Study 29779416 — intervention group
Group type: COMPARATOR
Intervention: Triple Therapy (tiotropium [18 μg] once daily plus salmeterol/fluticasone propionate [50/500 μg] twice daily)
Number of subjects: 1053
Study 26681262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin treatment spray (placebo)
Number of subjects: 77
Study 26681262 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin treatment spray (placebo)
Number of subjects: 77
Study 26681262 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 77
Study 24991714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral surgery
Number of subjects: 250
Study 24991714 — intervention group
Group type: COMPARATOR
Intervention: Dorsal surgery (laminectomy/fusion or laminoplasty)
Number of subjects: 250
Study 24991714 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative sagittal balance
Number of subjects: 250
Study 24991714 — intervention group
Group type: EXPERIMENTAL
Intervention: Health resource use for ventral procedures
Number of subjects: 250
Study 24991714 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall health-related quality of life
Number of subjects: 250
Study 22293126 — intervention group
Group type: EXPERIMENTAL
Intervention: Uridine (NucleomaxX(®); Pharma Nord)
Number of subjects: 50
Study 22293126 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir (TDF) switch
Number of subjects: 50
Study 19159693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (12 microg/kg)
Number of subjects: 24
Study 19159693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study 17234506 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation containing 460 mg of omega-3 polyunsaturated fatty acids and/or 580 mg of soluble fibers
Number of subjects: 99
Study 17234506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 16847182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal treatment with amphotericin B for 8 weeks
Number of subjects: 60
Study 16847182 — intervention group
Group type: COMPARATOR
Intervention: Saline control for 8 weeks
Number of subjects: 60
Study 16847182 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful fungus eradication
Number of subjects: 60
Study 14676082 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept, 25 mg, subcutaneously twice a week for 24 weeks
Number of subjects: 112
Study 14676082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 14676082 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 112
Study 14676082 — intervention group
Group type: COMPARATOR
Intervention: Etanercept and Placebo
Number of subjects: 112
Study 11030848 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion of 40 mg/kg
Number of subjects: 30
Study 11030848 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 30
Study 8796393 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of i.v. nicardipine
Number of subjects: 8
Study 1339758 — intervention group
Group type: EXPERIMENTAL
Intervention: Leponex (clozapine)
Number of subjects: 1062
Study 6722081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-dense supplement (A)
Number of subjects: 225
Study 6722081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (B)
Number of subjects: 225
Study 29763373 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose challenge (OGC, 50 g glucose)
Number of subjects: 15
Study 29763373 — intervention group
Group type: COMPARATOR
Intervention: Mixed-meal challenge (MMC)
Number of subjects: 15
Study 27956074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 15 weekly group sessions based on a CBT manual, commenced immediately after discharge.
Number of subjects: 155
Study 27956074 — intervention group
Group type: COMPARATOR
Intervention: Usual care during a 4-month waiting list interval.
Number of subjects: 155
Study 27956074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 15 weekly group sessions based on a CBT manual.
Number of subjects: 155
Study 25480457 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of prognostic data as frequencies (e.g., 1 in 50)
Number of subjects: 141
Study 25480457 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing qualitative data in terms of chance of death
Number of subjects: 141
Study 25480457 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing quantitative data in terms of chance of death
Number of subjects: 141
Study 23782653 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based task-specific reach-to-grasp (RTG) training, 14 training sessions, each 1 hour long, over 6 weeks, with encouragement for 1 hour/day independent practice (total of 56 hours).
Number of subjects: 50
Study 23782653 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm therapy.
Number of subjects: 50
Study 23782653 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based task-specific reach-to-grasp (RTG) training
Number of subjects: 50
Study 23782653 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm therapy
Number of subjects: 50
Study 21958767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 185
Study 21958767 — intervention group
Group type: COMPARATOR
Intervention: Standard lung closure
Number of subjects: 185
Study 18245179 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine plus metformin (15 mg/day + 750 mg/day)
Number of subjects: 40
Study 18245179 — intervention group
Group type: COMPARATOR
Intervention: olanzapine plus placebo (15 mg/day + placebo)
Number of subjects: 40
Study 18245179 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine plus metformin
Number of subjects: 40
Study 18245179 — intervention group
Group type: COMPARATOR
Intervention: olanzapine plus placebo
Number of subjects: 40
Study 16178291 — intervention group
Group type: EXPERIMENTAL
Intervention: Allevyn Adhesive
Number of subjects: 32
Study 16178291 — intervention group
Group type: COMPARATOR
Intervention: Biatain Adhesive
Number of subjects: 32
Study 12682319 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean daily dose of 2.5 +/- 0.85)
Number of subjects: 34
Study 12682319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12682319 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (in children)
Number of subjects: 34
Study 12682319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in children)
Number of subjects: 34
Study 12682319 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 34
Study 10637197 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP grade 3
Number of subjects: 762
Study 10637197 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP grade 2
Number of subjects: 762
Study 10637197 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP grades 0 and 1
Number of subjects: 762
Study 10637197 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP grades 0 or 1
Number of subjects: 762
Study 10637197 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count
Number of subjects: 762
Study 10637197 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anterior myocardial infarction
Number of subjects: 762
Study 10637197 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 762
Study 8969678 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of prostaglandin analogues to support gastric homeostasis
Number of subjects: 0
Study 8969678 — intervention group
Group type: EXPERIMENTAL
Intervention: Development or identification of an NSAID that targets inflammatory prostaglandins while sparing homeostatic ones
Number of subjects: 0
Study 1643676 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1
Number of subjects: 80
Study 1643676 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.75 mg.kg‐1
Number of subjects: 80
Study 1643676 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1.0 mg.kg‐1
Number of subjects: 80
Study 1643676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 6442057 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (oral gold salt)
Number of subjects: 0
Study 6442057 — intervention group
Group type: COMPARATOR
Intervention: Sodium aurothiomalate (parenteral gold salt)
Number of subjects: 0
Study 6442057 — intervention group
Group type: COMPARATOR
Intervention: Other baseline antirheumatoids (D-penicillamine, antimalarials)
Number of subjects: 0
Study 31978611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin for confirmed LF patients
Number of subjects: 150
Study 31978611 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized supportive care and biological monitoring
Number of subjects: 150